B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CDK8

MOLECULAR TARGET

cyclin dependent kinase 8

NCBI Gene: 102421 compounds

CDK8 (cyclin dependent kinase 8) is targeted by 21 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CDK8

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvocidib4.5291
2foretinib4.3476
3ponatinib4.2670
4doramapimod4.0657
5quizartinib3.9953
6dinaciclib3.8747
7vatalanib3.6939
8bms 3870323.4731
9tpck3.4731
10linifanib3.3327
11lestaurtinib3.0420
12plx 47202.7114
13ast 4872.5612
14cp 7247142.5612
15ct 70012.208
16sel 120 free base1.956
17voruciclib1.795
18Sorafenib1.393
19hydroxyfasudil [Supplementary Concept]1.102
20alsterpaullone0.691
21ly2940020.691

About CDK8 as a Drug Target

CDK8 (cyclin dependent kinase 8) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 21 compounds with documented CDK8 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CDK8 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.